Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYAT1 | Q16773 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2555896 | 0.84 | MMP8 (0.50) | CYP1A2MMP8MAPTMEN1KMT2A | |
| SCHEMBL3932315 | 0.82 | ALDH1A1 (0.45) | MAPTLMNAMAPK1ALDH1A1 | |
| SCHEMBL4875770 | 0.81 | SLC6A4 (0.46) | MMP8MAPTMEN1KMT2AS1PR4 | |
| SCHEMBL1437676 | 0.76 | MMP8 (0.54) | CYP1A2CYP2D6MMP8MEN1KMT2A | |
| SCHEMBL31635690 | 0.74 | PNMT (0.45) | KYAT1MAPTMEN1KMT2ALMNA | |
| SCHEMBL10561458 | 0.73 | DPP4 (0.46) | MMP8OPRM1 | |
| SCHEMBL10561451 | 0.73 | DPP4 (0.46) | MMP8OPRM1 | |
| SCHEMBL10680407 | 0.73 | DPP4 (0.46) | MMP8OPRM1 | |
| SCHEMBL5634815 | 0.73 | KYAT1 (0.43) | KYAT1CYP1A2MAPTMEN1KMT2A | |
| SCHEMBL13721762 | 0.73 | EPHX2 (0.44) | MMP8MAPTMEN1KMT2AS1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608365-B1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | R TECH UENO LTD (JP) | 2013-10-02 | — | — | EP | disclosed |
| CN-1794988-B | Composition for treating vascular hyperpermeable disease | SUCAMPO AG | 2010-07-28 | — | — | CN | disclosed |
| CN-100491361-C | Thiazole derivatives and their use as VAP-1 inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 2009-05-27 | — | — | CN | disclosed |
| US-7442715-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2008-10-28 | — | — | US | disclosed |
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-20060276521-A1 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-12-07 | — | — | US | disclosed |
| US-7125901-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-10-24 | — | — | US | disclosed |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-10-12 | — | — | US | disclosed |
| CN-1794988-A | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-06-28 | — | — | CN | disclosed |
| US-20060128770-A1 | Thiazole derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2006-06-15 | — | — | US | disclosed |
| CN-1761655-A | Thiazole derivatives and their use as VAP-1 inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 2006-04-19 | — | — | CN | disclosed |
| EP-1608365-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | Sucampo AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| EP-1587800-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS VAP-1 INHIBITORS | Astellas Pharma Inc. (JP) | 2005-10-26 | — | — | EP | disclosed |
| US-20040259923-A1 | Compound useful as cellular adhesion protein and as antiedemic agent | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-12-23 | — | — | US | disclosed |
| WO-2004087138-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004067521-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS VAP-1 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | VCAM1, ICAM1, VAPB | KYAT1 4452/4885CYP1A2 4127/4885CYP2D6 4546/4885 |
| US-20060276521-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | KYAT1 2196/4885CYP1A2 4379/4885CYP2D6 4598/4885 |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | VCAM1, VAPB, ICAM1 | KYAT1 2534/4885CYP1A2 3378/4885CYP2D6 4095/4885 |
| US-20060128770-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | KYAT1 2196/4885CYP1A2 4379/4885CYP2D6 4598/4885 |
| US-20040259923-A1 | Compound useful as cellular adhesion protein and as antiedemic agent | VCAM1, ICAM1, VAPB | KYAT1 3945/4885CYP1A2 4852/4885CYP2D6 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.